TY - CHAP A1 - S├ębastien Lefebvre A2 - Etienne Benoit A3 - Virginie Lattard ED1 - Ozcan Basaran ED2 - Murat Biteker Y1 - 2016-09-08 PY - 2016 T1 - Comparative Biology of the Resistance to Vitamin K Antagonists: An Overview of the Resistance Mechanisms N2 - The available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase III trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists. BT - Anticoagulation Therapy SP - Ch. 2 UR - https://doi.org/10.5772/64204 DO - 10.5772/64204 SN - 978-953-51-2667-6 PB - IntechOpen CY - Rijeka Y2 - 2021-06-21 ER -